Seeking Alpha
 

ACADIA Pharmaceuticals Inc. (ACAD)

- NASDAQ
  • Nov. 1, 2013, 8:32 AM
    • Acadia Pharmaceuticals (ACAD) announces the publication of Phase 3 pimavanserin results in PDP.
    • The data, published today in The Lancet, shows "pimavanserin met the primary endpoint ... by demonstrating highly significant improvement in psychosis compared to placebo on the 9-item SAPS-PD scale."
    • "The mean change in SAPS-PD score represented a 37% improvement for pimavanserin versus 14% for placebo," the company notes. (PR)
    • ACAD +6% premarket
    | Comment!
  • Oct. 14, 2013, 2:51 PM
    • Acadia Pharmaceuticals (ACAD +9.3%) is enjoying a strong session.
    • Perhaps helping to tip sentiment is SA Contributor Brian Nichols, who says the company's antipsychotic drug pimavanserin has "the greatest sales potential since Lipitor" — good news, considering Lipitor is the best-selling drug in pharmaceutical history.
    • Nichols goes on to predict peak global sales of $20.45B, and says his "five key points ... suggest that sales could be even greater."
    • As for a target price, Nichols says three times sales for companies with assumed blockbusters (cited are Alexion and Pharmacyclics) isn't unreasonable, and just to be on the safe side, the author discounts peak sales by "a whopping 50%," then multiplies $10B times three to get a valuation of ~$30B.
    • Ultimately, Nichols says "a target price over $300 is not unrealistic." This represents upside of around 1,295% from Friday's close.
    | 13 Comments
  • Oct. 11, 2013, 9:26 AM
    • It appears a large number of NPS Pharmaceuticals (NPSP) shares were sold Friday morning at $32 each.
    • The company itself was not a part of the transaction. According to NPSP, "these were shares that were held by Takeda that they sold to Jefferies in a block trade and Jefferies has re-sold the shares through its sales distribution network."
    • Thursday evening, Cramer recommended "ringing the register on pretty much any biotech that's smaller than $10B." Stocks mentioned: NPSP, ISIS, CLDX, ACAD, TSRO
    | 12 Comments
  • Oct. 10, 2013, 12:45 PM
    | Comment!
  • Oct. 8, 2013, 12:45 PM
    | Comment!
  • Oct. 8, 2013, 10:58 AM
    • Acadia Pharmaceuticals (ACAD -17.9%) shares are down sharply, with no recent news or information to account for the move, though biotech blogger Adam Feuerstein tweets a rumor that today's decline is due to a doctor on a Cowen panel having a bearish stance on its lead drug candidate pimavanserin.
    • Pimavanserin is in Phase 3 development as a potential first-in-class treatment for Parkinson's disease psychosis, and ACAD established an expedited path to an NDA filing in Q2.
    • Shares are up 403% YTD.
    | 11 Comments
  • Oct. 7, 2013, 5:45 PM
    • Top Gainers, as of 5:15 p.m.: TLM +13.7%. ANV +3.5%. ZSL +2.2%. ACAD +2.1%. NBG +2.0%.
    • Top Losers, as of 5:15 p.m.: TWGP -26.8%. NES -10.9%. JMBA -8.6%. NQ -4.8%. MBT -3.6%.
    | Comment!
  • Aug. 7, 2013, 12:31 PM
    • Acadia Pharmaceuticals (ACAD -3.3%) slips after MLV & Co. cut the shares from Buy to Hold, but ups its price target from $18 to $20.
    • The firm says that although it was a "transformational" quarter for the company, the stock has reached fair value for now.
    | 1 Comment
  • Aug. 7, 2013, 10:19 AM
    • Sentiment turns sour on Acadia Pharmaceuticals (ACAD -4.7%) following Tuesday's Q2 report.
    • Undeterred is Needham's Alan Carr who lifts his price target on the shares to $26 (from $16) citing a likely H2 2015 approval for pimavanserin in Parkinson's Disease Psychosis.
    | 1 Comment
  • Aug. 7, 2013, 12:49 AM
    • ACADIA (ACAD): Q2 EPS of -$0.11 misses by $0.02.
    • Revenue of $451K beats by $1K (PR)
    | Comment!
  • Jun. 18, 2013, 9:31 AM
    Acadia Pharmaceuticals (ACAD +0.4%) says data from a Phase III trial of pimavanserin suggest the treatment is well-tolerated and effective when administered long-term. (See also: JMP, SA contributor weigh in on ACAD)
    | 1 Comment
  • Jun. 14, 2013, 9:52 AM
    JMP (Outperform) boosts its price target on Acadia Pharmaceuticals (ACAD +3.2%) to $27 from $16. SA contributor PTSD Trader recently said pimavanserin is the "silver lining in the company's playbook."
    | Comment!
  • Jun. 14, 2013, 9:19 AM
    Premarket gainers: RH +13%. PXLW +11%. GRPN +8%. SCTY +8%. SYRG +6%. INVN +6%. ACAD +6%. SWHC +5%.
    Losers: CEMP -14%. AMSC -9%. HIMX -7%. CLSN -5%.
    | Comment!
  • Jun. 10, 2013, 12:45 PM
    Midday top 10 gainers: SGOC +25%. ACAD +17%. STEL +17%. MPAA +14%. TRMD +9%. OVAS +13%. CLIR +13%. TPLM +12%. RVLT +13%. KNDI +12%.
    Midday top 10 Losers: DVAX -35%. OSH -18%. ECTE -16%. AFFY -14%. AEPI -14%. OMX -12%. SHI -12%. PLM -11%. GNRC -11%. CBAK -11%.
    | 1 Comment
  • May 14, 2013, 4:14 PM
    Acadia Pharmaceuticals (ACAD) announces a public offering. Size and terms of the offering weren't disclosed. Jefferies and Cowen are acting as the joint book-running managers for the offering. Shares -5% AH.
    | Comment!
  • May 7, 2013, 8:05 PM
    ACADIA (ACAD): Q1 EPS of -$0.08 in-line. Revenue of $417K misses by $33K. (PR)
    | Comment!
Visit Seeking Alpha's
ACAD vs. ETF Alternatives
Company Description
ACADIA Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the business of development and commercialization of small molecule drugs for the treatment of central nervous system disorders.
Sector: Healthcare
Industry: Biotechnology
Country: United States